 Douglas Fish
Concepts (596)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Infective Agents | 20 | 2016 | 255 | 2.230 |
Why?
| | Anti-Bacterial Agents | 30 | 2024 | 1809 | 2.160 |
Why?
| | Microbial Sensitivity Tests | 17 | 2024 | 361 | 1.800 |
Why?
| | Cephalexin | 2 | 2024 | 12 | 1.630 |
Why?
| | Staphylococcal Infections | 6 | 2024 | 400 | 1.360 |
Why?
| | Vancomycin | 6 | 2024 | 84 | 1.340 |
Why?
| | Cefadroxil | 2 | 2024 | 10 | 1.070 |
Why?
| | Surgical Wound Infection | 6 | 2016 | 307 | 1.030 |
Why?
| | Sepsis | 7 | 2020 | 617 | 0.970 |
Why?
| | Fluoroquinolones | 8 | 2007 | 51 | 0.960 |
Why?
| | Endocarditis | 3 | 2024 | 37 | 0.950 |
Why?
| | Critical Illness | 23 | 2022 | 811 | 0.890 |
Why?
| | Antibiotic Prophylaxis | 8 | 2016 | 119 | 0.890 |
Why?
| | Ofloxacin | 7 | 2006 | 24 | 0.870 |
Why?
| | Levofloxacin | 7 | 2006 | 27 | 0.870 |
Why?
| | Endocarditis, Bacterial | 1 | 2024 | 41 | 0.830 |
Why?
| | Pseudomonas Infections | 5 | 2013 | 225 | 0.780 |
Why?
| | Prodrugs | 4 | 2009 | 52 | 0.780 |
Why?
| | Cross-Over Studies | 3 | 2024 | 564 | 0.760 |
Why?
| | Bacterial Infections | 7 | 2009 | 250 | 0.720 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 250 | 0.720 |
Why?
| | Hemofiltration | 8 | 2022 | 30 | 0.700 |
Why?
| | Cross Infection | 6 | 2011 | 256 | 0.660 |
Why?
| | Renal Replacement Therapy | 4 | 2015 | 92 | 0.650 |
Why?
| | Pseudomonas aeruginosa | 7 | 2013 | 352 | 0.650 |
Why?
| | Antiviral Agents | 7 | 2012 | 744 | 0.640 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2020 | 234 | 0.630 |
Why?
| | Intensive Care Units | 17 | 2016 | 827 | 0.630 |
Why?
| | Anticoagulants | 6 | 2016 | 664 | 0.630 |
Why?
| | Education, Pharmacy | 2 | 2014 | 120 | 0.630 |
Why?
| | Heparin | 6 | 2016 | 261 | 0.630 |
Why?
| | Valine | 6 | 2008 | 82 | 0.610 |
Why?
| | Acyclovir | 6 | 2008 | 101 | 0.600 |
Why?
| | Acute Kidney Injury | 4 | 2024 | 815 | 0.570 |
Why?
| | Vitreous Body | 2 | 2009 | 110 | 0.560 |
Why?
| | beta-Lactams | 2 | 2020 | 33 | 0.550 |
Why?
| | Cephalosporins | 4 | 2012 | 48 | 0.540 |
Why?
| | Critical Care | 11 | 2016 | 601 | 0.540 |
Why?
| | Humans | 128 | 2024 | 137585 | 0.530 |
Why?
| | AIDS Serodiagnosis | 1 | 2017 | 24 | 0.530 |
Why?
| | Cefoxitin | 1 | 2016 | 8 | 0.520 |
Why?
| | Staphylococcus aureus | 4 | 2024 | 450 | 0.480 |
Why?
| | Antifungal Agents | 6 | 2019 | 136 | 0.470 |
Why?
| | Obesity, Morbid | 2 | 2016 | 264 | 0.470 |
Why?
| | Students, Pharmacy | 2 | 2014 | 97 | 0.460 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2014 | 29 | 0.460 |
Why?
| | Histamine H2 Antagonists | 1 | 2014 | 30 | 0.450 |
Why?
| | Drug Resistance, Microbial | 4 | 2006 | 71 | 0.450 |
Why?
| | Thrombocytopenia | 3 | 2009 | 200 | 0.440 |
Why?
| | Pharmacy Service, Hospital | 3 | 2014 | 90 | 0.440 |
Why?
| | Problem-Based Learning | 2 | 2017 | 92 | 0.440 |
Why?
| | Middle Aged | 54 | 2024 | 33479 | 0.440 |
Why?
| | Pneumonia | 4 | 2014 | 639 | 0.420 |
Why?
| | Proton Pump Inhibitors | 1 | 2014 | 109 | 0.420 |
Why?
| | Peritonitis | 2 | 2016 | 84 | 0.410 |
Why?
| | Pneumonia, Bacterial | 2 | 2013 | 116 | 0.410 |
Why?
| | HIV Infections | 7 | 2017 | 2836 | 0.410 |
Why?
| | Voriconazole | 3 | 2019 | 20 | 0.410 |
Why?
| | Hepatorenal Syndrome | 3 | 2013 | 16 | 0.400 |
Why?
| | Hirudins | 4 | 2010 | 53 | 0.400 |
Why?
| | Colorectal Surgery | 1 | 2012 | 24 | 0.390 |
Why?
| | Administration, Oral | 12 | 2019 | 816 | 0.390 |
Why?
| | Community-Acquired Infections | 1 | 2014 | 174 | 0.390 |
Why?
| | Male | 65 | 2024 | 67762 | 0.380 |
Why?
| | Aged | 38 | 2024 | 23961 | 0.370 |
Why?
| | Teaching | 1 | 2014 | 224 | 0.370 |
Why?
| | Liver Cirrhosis | 3 | 2009 | 316 | 0.360 |
Why?
| | Adult | 48 | 2024 | 37929 | 0.360 |
Why?
| | Preoperative Care | 2 | 2012 | 362 | 0.350 |
Why?
| | Female | 63 | 2024 | 73304 | 0.340 |
Why?
| | Interpersonal Relations | 1 | 2014 | 397 | 0.340 |
Why?
| | Drug Resistance, Multiple | 1 | 2010 | 25 | 0.340 |
Why?
| | Cefazolin | 2 | 2022 | 21 | 0.340 |
Why?
| | Imipenem | 3 | 2010 | 18 | 0.340 |
Why?
| | Enteral Nutrition | 4 | 2008 | 202 | 0.340 |
Why?
| | Burns | 3 | 2018 | 325 | 0.340 |
Why?
| | Syringes | 2 | 2007 | 44 | 0.330 |
Why?
| | Penicillanic Acid | 2 | 2013 | 5 | 0.330 |
Why?
| | Chromatography, High Pressure Liquid | 9 | 2012 | 597 | 0.320 |
Why?
| | Prospective Studies | 17 | 2024 | 7604 | 0.320 |
Why?
| | Dexmedetomidine | 3 | 2014 | 43 | 0.320 |
Why?
| | Drug Resistance, Multiple, Bacterial | 4 | 2005 | 78 | 0.320 |
Why?
| | 2-Aminopurine | 1 | 2009 | 9 | 0.310 |
Why?
| | Peptide Fragments | 3 | 2010 | 706 | 0.310 |
Why?
| | HIV Protease Inhibitors | 2 | 2000 | 69 | 0.310 |
Why?
| | Recombinant Proteins | 6 | 2010 | 1353 | 0.300 |
Why?
| | Peptic Ulcer | 2 | 2014 | 20 | 0.290 |
Why?
| | Monte Carlo Method | 3 | 2016 | 148 | 0.290 |
Why?
| | Retrospective Studies | 23 | 2024 | 15657 | 0.280 |
Why?
| | Polypropylenes | 1 | 2007 | 13 | 0.270 |
Why?
| | Drug Delivery Systems | 2 | 2006 | 365 | 0.270 |
Why?
| | Sympathomimetics | 1 | 2007 | 21 | 0.270 |
Why?
| | Protein C | 2 | 2010 | 59 | 0.270 |
Why?
| | Infection Control | 3 | 2010 | 167 | 0.270 |
Why?
| | Expectorants | 1 | 2007 | 24 | 0.270 |
Why?
| | Phenylephrine | 1 | 2007 | 75 | 0.270 |
Why?
| | Drug Monitoring | 6 | 2017 | 218 | 0.270 |
Why?
| | Clarithromycin | 2 | 1999 | 28 | 0.270 |
Why?
| | Accreditation | 1 | 2007 | 83 | 0.270 |
Why?
| | Triazoles | 2 | 2019 | 147 | 0.270 |
Why?
| | Community Pharmacy Services | 1 | 2007 | 45 | 0.260 |
Why?
| | Drug Packaging | 1 | 2007 | 45 | 0.260 |
Why?
| | Aged, 80 and over | 16 | 2018 | 7635 | 0.260 |
Why?
| | Hypnotics and Sedatives | 3 | 2014 | 200 | 0.250 |
Why?
| | Acetylcysteine | 1 | 2007 | 145 | 0.250 |
Why?
| | Educational Measurement | 3 | 2017 | 289 | 0.250 |
Why?
| | Emergency Service, Hospital | 2 | 2017 | 2069 | 0.250 |
Why?
| | Piperacillin | 2 | 2013 | 9 | 0.250 |
Why?
| | Pipecolic Acids | 1 | 2005 | 26 | 0.240 |
Why?
| | Models, Biological | 1 | 2013 | 1783 | 0.240 |
Why?
| | Penicillins | 2 | 2004 | 58 | 0.240 |
Why?
| | Drug Interactions | 6 | 2013 | 410 | 0.240 |
Why?
| | Ketolides | 1 | 2005 | 1 | 0.240 |
Why?
| | Kidney Diseases | 3 | 2009 | 408 | 0.240 |
Why?
| | Thrombin | 1 | 2006 | 152 | 0.230 |
Why?
| | Bacteria | 4 | 2022 | 858 | 0.220 |
Why?
| | Nursing Homes | 3 | 2011 | 181 | 0.220 |
Why?
| | Enterobacter cloacae | 1 | 2004 | 5 | 0.220 |
Why?
| | Area Under Curve | 7 | 2008 | 314 | 0.220 |
Why?
| | Aza Compounds | 1 | 2004 | 14 | 0.220 |
Why?
| | Acinetobacter baumannii | 1 | 2004 | 21 | 0.220 |
Why?
| | Half-Life | 6 | 2012 | 164 | 0.220 |
Why?
| | Klebsiella pneumoniae | 1 | 2004 | 47 | 0.210 |
Why?
| | Bacteremia | 3 | 2018 | 214 | 0.210 |
Why?
| | Respiratory Tract Infections | 2 | 2005 | 390 | 0.210 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2828 | 0.210 |
Why?
| | Anticonvulsants | 2 | 2017 | 217 | 0.210 |
Why?
| | Drug Storage | 4 | 2007 | 57 | 0.210 |
Why?
| | Drug Stability | 4 | 2007 | 167 | 0.200 |
Why?
| | Obesity | 1 | 2016 | 2992 | 0.200 |
Why?
| | Tissue Distribution | 3 | 2016 | 332 | 0.200 |
Why?
| | Liver Diseases | 1 | 2006 | 315 | 0.200 |
Why?
| | Quinolines | 1 | 2004 | 178 | 0.200 |
Why?
| | AIDS-Related Opportunistic Infections | 2 | 1993 | 127 | 0.200 |
Why?
| | Cephalothin | 1 | 2022 | 6 | 0.200 |
Why?
| | Oxacillin | 1 | 2022 | 6 | 0.200 |
Why?
| | Methicillin | 1 | 2022 | 11 | 0.200 |
Why?
| | Bronchoscopy | 1 | 2003 | 223 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2016 | 2057 | 0.190 |
Why?
| | Infusions, Intravenous | 7 | 2016 | 413 | 0.190 |
Why?
| | Drug Therapy, Combination | 8 | 2016 | 1066 | 0.190 |
Why?
| | Anti-HIV Agents | 2 | 1999 | 778 | 0.190 |
Why?
| | Lorazepam | 2 | 2014 | 27 | 0.190 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2014 | 179 | 0.190 |
Why?
| | Bronchi | 1 | 2003 | 260 | 0.190 |
Why?
| | Antacids | 1 | 2001 | 16 | 0.190 |
Why?
| | Quinolones | 1 | 2003 | 137 | 0.180 |
Why?
| | Liver Transplantation | 1 | 2009 | 871 | 0.180 |
Why?
| | Catheters, Indwelling | 2 | 2016 | 91 | 0.180 |
Why?
| | Kidney Failure, Chronic | 5 | 2016 | 570 | 0.180 |
Why?
| | Hemodiafiltration | 2 | 2005 | 9 | 0.180 |
Why?
| | Lyme Disease | 4 | 2001 | 60 | 0.180 |
Why?
| | Ciprofloxacin | 3 | 2004 | 29 | 0.170 |
Why?
| | Fibrinolytic Agents | 2 | 2016 | 270 | 0.170 |
Why?
| | Colorado | 12 | 2021 | 4565 | 0.170 |
Why?
| | Antidiarrheals | 1 | 2000 | 15 | 0.170 |
Why?
| | Fludrocortisone | 1 | 2000 | 3 | 0.170 |
Why?
| | Mineralocorticoids | 1 | 2000 | 8 | 0.170 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 840 | 0.170 |
Why?
| | Public Health Administration | 1 | 2021 | 76 | 0.170 |
Why?
| | Naphthyridines | 1 | 2000 | 19 | 0.170 |
Why?
| | Octreotide | 2 | 2013 | 26 | 0.170 |
Why?
| | Multivariate Analysis | 6 | 2017 | 1509 | 0.160 |
Why?
| | Hyperkalemia | 1 | 2000 | 24 | 0.160 |
Why?
| | Lung Transplantation | 2 | 2014 | 313 | 0.160 |
Why?
| | Multiple Organ Failure | 2 | 2010 | 128 | 0.160 |
Why?
| | Ethanol | 2 | 2014 | 608 | 0.160 |
Why?
| | Clinical Competence | 1 | 2007 | 1118 | 0.160 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 11 | 0.150 |
Why?
| | New York | 3 | 2017 | 126 | 0.150 |
Why?
| | Thienamycins | 2 | 2005 | 5 | 0.150 |
Why?
| | Diarrhea | 1 | 2000 | 184 | 0.150 |
Why?
| | Cytosine | 1 | 1999 | 49 | 0.150 |
Why?
| | Practice Guidelines as Topic | 5 | 2016 | 1587 | 0.150 |
Why?
| | Hydroxyurea | 1 | 1999 | 35 | 0.150 |
Why?
| | Bites and Stings | 4 | 2001 | 32 | 0.150 |
Why?
| | Nafcillin | 1 | 2018 | 3 | 0.150 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 301 | 0.150 |
Why?
| | Organophosphonates | 1 | 1999 | 93 | 0.150 |
Why?
| | APACHE | 3 | 2010 | 69 | 0.150 |
Why?
| | Schools, Pharmacy | 2 | 2017 | 47 | 0.150 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 1998 | 84 | 0.150 |
Why?
| | Organophosphorus Compounds | 1 | 1999 | 78 | 0.150 |
Why?
| | Clostridium Infections | 1 | 2019 | 73 | 0.150 |
Why?
| | Gastric Emptying | 2 | 2008 | 38 | 0.140 |
Why?
| | Nitriles | 1 | 2019 | 172 | 0.140 |
Why?
| | Cohort Studies | 7 | 2013 | 5742 | 0.140 |
Why?
| | Vitrectomy | 2 | 2009 | 70 | 0.140 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 170 | 0.140 |
Why?
| | Pharmaceutical Services | 1 | 1998 | 83 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 1997 | 6 | 0.140 |
Why?
| | Adolescent | 15 | 2024 | 21513 | 0.140 |
Why?
| | Atracurium | 1 | 1997 | 14 | 0.140 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 1997 | 17 | 0.140 |
Why?
| | Communicable Diseases | 1 | 2020 | 159 | 0.140 |
Why?
| | Sumatriptan | 1 | 1997 | 8 | 0.140 |
Why?
| | Gastrointestinal Agents | 2 | 2008 | 65 | 0.140 |
Why?
| | Serotonin Receptor Agonists | 1 | 1997 | 26 | 0.140 |
Why?
| | Antibodies, Bacterial | 1 | 2018 | 146 | 0.140 |
Why?
| | Piracetam | 1 | 2017 | 13 | 0.140 |
Why?
| | Immunity, Humoral | 1 | 2018 | 116 | 0.140 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2017 | 17 | 0.130 |
Why?
| | Hematologic Neoplasms | 1 | 2019 | 156 | 0.130 |
Why?
| | Vasodilator Agents | 2 | 2016 | 331 | 0.130 |
Why?
| | Cardiopulmonary Bypass | 2 | 2016 | 209 | 0.130 |
Why?
| | Treatment Outcome | 10 | 2018 | 10811 | 0.130 |
Why?
| | Hydrogen-Ion Concentration | 4 | 2014 | 560 | 0.130 |
Why?
| | Pneumococcal Vaccines | 1 | 2018 | 142 | 0.130 |
Why?
| | Drug Administration Schedule | 5 | 2018 | 786 | 0.130 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 85 | 0.130 |
Why?
| | Thiocyanates | 1 | 2016 | 31 | 0.130 |
Why?
| | Nitroprusside | 1 | 2016 | 69 | 0.130 |
Why?
| | Thiosulfates | 1 | 2016 | 19 | 0.130 |
Why?
| | Administration, Intravenous | 2 | 2017 | 155 | 0.130 |
Why?
| | Neurosurgical Procedures | 1 | 2018 | 197 | 0.130 |
Why?
| | Pneumonectomy | 1 | 1998 | 152 | 0.130 |
Why?
| | Toxoplasmosis, Cerebral | 1 | 1995 | 3 | 0.120 |
Why?
| | Benzodiazepines | 2 | 2014 | 155 | 0.120 |
Why?
| | Partial Thromboplastin Time | 2 | 2006 | 57 | 0.120 |
Why?
| | Naphthoquinones | 1 | 1995 | 19 | 0.120 |
Why?
| | Famotidine | 1 | 1995 | 2 | 0.120 |
Why?
| | Antiprotozoal Agents | 1 | 1995 | 16 | 0.120 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 1997 | 70 | 0.120 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1995 | 38 | 0.120 |
Why?
| | Pyridines | 1 | 2019 | 506 | 0.120 |
Why?
| | Child | 7 | 2024 | 21935 | 0.120 |
Why?
| | Drug Resistance | 2 | 2011 | 169 | 0.120 |
Why?
| | Therapeutics | 1 | 2015 | 14 | 0.120 |
Why?
| | Peptic Ulcer Hemorrhage | 1 | 2014 | 6 | 0.120 |
Why?
| | Drug Utilization Review | 1 | 1995 | 57 | 0.120 |
Why?
| | Injections, Intravenous | 5 | 2012 | 206 | 0.120 |
Why?
| | beta-Cyclodextrins | 1 | 2015 | 28 | 0.110 |
Why?
| | Body Weight | 2 | 2016 | 985 | 0.110 |
Why?
| | Anti-Ulcer Agents | 1 | 2014 | 16 | 0.110 |
Why?
| | Peritoneal Dialysis | 1 | 2016 | 97 | 0.110 |
Why?
| | Academic Medical Centers | 2 | 2019 | 512 | 0.110 |
Why?
| | Antidotes | 1 | 2016 | 143 | 0.110 |
Why?
| | Diltiazem | 1 | 2014 | 29 | 0.110 |
Why?
| | Mass Casualty Incidents | 1 | 2014 | 38 | 0.110 |
Why?
| | Drug Dosage Calculations | 1 | 2014 | 23 | 0.110 |
Why?
| | Biopsy | 1 | 1998 | 1129 | 0.110 |
Why?
| | Vasopressins | 2 | 2004 | 64 | 0.110 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 2014 | 20 | 0.110 |
Why?
| | Temperature | 2 | 2007 | 679 | 0.110 |
Why?
| | Osmotic Pressure | 1 | 2014 | 38 | 0.110 |
Why?
| | Biological Availability | 4 | 2009 | 148 | 0.110 |
Why?
| | Somatostatin | 1 | 2013 | 61 | 0.110 |
Why?
| | Immunoglobulin G | 1 | 2018 | 893 | 0.110 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 1993 | 21 | 0.110 |
Why?
| | Infant | 5 | 2024 | 9465 | 0.110 |
Why?
| | Vasoconstrictor Agents | 2 | 2004 | 139 | 0.100 |
Why?
| | Creatinine | 3 | 2007 | 499 | 0.100 |
Why?
| | Midazolam | 1 | 2013 | 56 | 0.100 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2019 | 622 | 0.100 |
Why?
| | Surveys and Questionnaires | 6 | 2017 | 5778 | 0.100 |
Why?
| | Homicide | 1 | 2014 | 69 | 0.100 |
Why?
| | Zidovudine | 1 | 1993 | 78 | 0.100 |
Why?
| | Child, Preschool | 6 | 2024 | 11074 | 0.100 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2014 | 132 | 0.100 |
Why?
| | Health Care Costs | 1 | 2017 | 398 | 0.100 |
Why?
| | Attitude to Health | 1 | 2017 | 439 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2001 | 1100 | 0.100 |
Why?
| | Nursing Staff | 2 | 2010 | 50 | 0.100 |
Why?
| | Bacteroides fragilis | 1 | 2012 | 13 | 0.100 |
Why?
| | Ticks | 2 | 1993 | 25 | 0.100 |
Why?
| | Lung | 2 | 1998 | 4060 | 0.100 |
Why?
| | Conscious Sedation | 1 | 2013 | 92 | 0.100 |
Why?
| | Risk Factors | 9 | 2014 | 10388 | 0.100 |
Why?
| | Program Evaluation | 1 | 2017 | 898 | 0.100 |
Why?
| | Vasoconstriction | 1 | 2014 | 202 | 0.100 |
Why?
| | Drug Synergism | 2 | 2004 | 382 | 0.100 |
Why?
| | Bone Cements | 1 | 1992 | 43 | 0.100 |
Why?
| | Renal Dialysis | 3 | 2022 | 435 | 0.100 |
Why?
| | Sirolimus | 1 | 2014 | 276 | 0.100 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1993 | 230 | 0.090 |
Why?
| | Enterococcus | 1 | 1992 | 23 | 0.090 |
Why?
| | Comprehension | 1 | 2014 | 172 | 0.090 |
Why?
| | Transplant Recipients | 1 | 2014 | 184 | 0.090 |
Why?
| | Treatment Failure | 1 | 2013 | 356 | 0.090 |
Why?
| | Ganciclovir | 1 | 2012 | 53 | 0.090 |
Why?
| | Coronary Artery Bypass | 1 | 2014 | 234 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 862 | 0.090 |
Why?
| | Mental Recall | 1 | 2013 | 202 | 0.090 |
Why?
| | Long QT Syndrome | 1 | 2013 | 70 | 0.090 |
Why?
| | Shock, Septic | 2 | 2004 | 219 | 0.090 |
Why?
| | Clinical Trials as Topic | 4 | 2000 | 1050 | 0.090 |
Why?
| | Metoclopramide | 2 | 2008 | 19 | 0.090 |
Why?
| | Occupational Diseases | 1 | 1993 | 156 | 0.090 |
Why?
| | Educational Status | 1 | 2014 | 470 | 0.090 |
Why?
| | Erythromycin | 2 | 2008 | 25 | 0.090 |
Why?
| | Drug Resistance, Multiple, Fungal | 1 | 2011 | 1 | 0.090 |
Why?
| | Metabolic Clearance Rate | 4 | 2012 | 115 | 0.090 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2014 | 180 | 0.090 |
Why?
| | Traction | 1 | 1991 | 20 | 0.090 |
Why?
| | Candida | 1 | 2011 | 38 | 0.090 |
Why?
| | Curriculum | 2 | 2017 | 992 | 0.090 |
Why?
| | Candidiasis | 1 | 2011 | 56 | 0.090 |
Why?
| | Anti-Anxiety Agents | 1 | 1991 | 46 | 0.090 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2011 | 26 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2014 | 660 | 0.090 |
Why?
| | Suspensions | 3 | 2002 | 36 | 0.090 |
Why?
| | Wounds, Gunshot | 1 | 2014 | 228 | 0.090 |
Why?
| | Hip Dislocation, Congenital | 1 | 1991 | 38 | 0.090 |
Why?
| | Neuromuscular Blockade | 1 | 2011 | 31 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 3 | 2014 | 1313 | 0.090 |
Why?
| | Aortic Valve | 1 | 2014 | 351 | 0.090 |
Why?
| | Genes, Regulator | 1 | 2010 | 37 | 0.080 |
Why?
| | Vancomycin Resistance | 1 | 2010 | 16 | 0.080 |
Why?
| | Primary Health Care | 1 | 2021 | 1738 | 0.080 |
Why?
| | Virus Activation | 2 | 2001 | 88 | 0.080 |
Why?
| | Cytomegalovirus Infections | 1 | 2012 | 192 | 0.080 |
Why?
| | Double-Blind Method | 6 | 2014 | 1993 | 0.080 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2002 | 106 | 0.080 |
Why?
| | Hypothermia, Induced | 1 | 2011 | 80 | 0.080 |
Why?
| | Pharmaceutical Vehicles | 1 | 2009 | 12 | 0.080 |
Why?
| | Propylene Glycol | 1 | 2009 | 10 | 0.080 |
Why?
| | Recurrence | 2 | 2009 | 1060 | 0.080 |
Why?
| | Delirium | 1 | 1991 | 92 | 0.080 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 345 | 0.080 |
Why?
| | Electrocardiography | 1 | 2013 | 629 | 0.080 |
Why?
| | Time Factors | 9 | 2014 | 6828 | 0.080 |
Why?
| | Herpesvirus 1, Human | 2 | 2001 | 87 | 0.080 |
Why?
| | Cornea | 2 | 2001 | 138 | 0.080 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 2009 | 8 | 0.080 |
Why?
| | Guideline Adherence | 2 | 2011 | 556 | 0.080 |
Why?
| | Eye Infections, Viral | 1 | 2009 | 9 | 0.080 |
Why?
| | Antipsychotic Agents | 1 | 1991 | 194 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 1946 | 0.080 |
Why?
| | Regression Analysis | 4 | 2016 | 1024 | 0.080 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 44 | 0.080 |
Why?
| | Education, Continuing | 1 | 2009 | 39 | 0.080 |
Why?
| | Tick Infestations | 1 | 1988 | 4 | 0.080 |
Why?
| | Patients | 1 | 2010 | 175 | 0.070 |
Why?
| | Models, Statistical | 1 | 2012 | 669 | 0.070 |
Why?
| | Escherichia coli | 1 | 2012 | 815 | 0.070 |
Why?
| | Mass Screening | 1 | 2017 | 1287 | 0.070 |
Why?
| | Acetaminophen | 2 | 2008 | 268 | 0.070 |
Why?
| | Immunization Programs | 1 | 2010 | 213 | 0.070 |
Why?
| | Communication | 1 | 2014 | 879 | 0.070 |
Why?
| | Young Adult | 5 | 2019 | 13209 | 0.070 |
Why?
| | Pharmacists | 3 | 2020 | 265 | 0.070 |
Why?
| | Antitubercular Agents | 2 | 1999 | 206 | 0.070 |
Why?
| | Lung Diseases | 1 | 2014 | 767 | 0.070 |
Why?
| | Cost Control | 1 | 2007 | 39 | 0.070 |
Why?
| | Health Personnel | 1 | 1993 | 710 | 0.070 |
Why?
| | Chronic Disease | 1 | 2013 | 1793 | 0.070 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 2007 | 30 | 0.070 |
Why?
| | Incidence | 3 | 2006 | 2804 | 0.060 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2008 | 125 | 0.060 |
Why?
| | Cerebrospinal Fluid | 1 | 2007 | 92 | 0.060 |
Why?
| | Glutamine | 1 | 2007 | 103 | 0.060 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 24 | 0.060 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2006 | 74 | 0.060 |
Why?
| | Preceptorship | 1 | 2006 | 66 | 0.060 |
Why?
| | Cilastatin | 1 | 2005 | 2 | 0.060 |
Why?
| | Drug Costs | 2 | 1999 | 106 | 0.060 |
Why?
| | Arginine Vasopressin | 1 | 2005 | 44 | 0.060 |
Why?
| | Platelet Activation | 1 | 2005 | 93 | 0.060 |
Why?
| | Platelet Aggregation | 1 | 2005 | 103 | 0.060 |
Why?
| | Chromatography, Liquid | 1 | 2007 | 433 | 0.060 |
Why?
| | United States | 6 | 2014 | 14841 | 0.060 |
Why?
| | Central Nervous System | 1 | 2007 | 258 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 2607 | 0.060 |
Why?
| | Cyclosporine | 2 | 2006 | 268 | 0.060 |
Why?
| | Protease Inhibitors | 1 | 2005 | 107 | 0.060 |
Why?
| | Animals | 11 | 2014 | 36940 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2016 | 431 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2014 | 3556 | 0.050 |
Why?
| | Acinetobacter Infections | 1 | 2004 | 14 | 0.050 |
Why?
| | Virus Shedding | 2 | 2001 | 48 | 0.050 |
Why?
| | Intubation, Gastrointestinal | 2 | 2008 | 79 | 0.050 |
Why?
| | Arginine | 1 | 2005 | 271 | 0.050 |
Why?
| | Borrelia burgdorferi Group | 2 | 2001 | 9 | 0.050 |
Why?
| | Klebsiella Infections | 1 | 2004 | 26 | 0.050 |
Why?
| | Influenza, Human | 1 | 2010 | 622 | 0.050 |
Why?
| | Colony Count, Microbial | 1 | 2004 | 120 | 0.050 |
Why?
| | Ixodes | 2 | 2001 | 14 | 0.050 |
Why?
| | Enterobacteriaceae Infections | 1 | 2004 | 43 | 0.050 |
Why?
| | Graft vs Host Disease | 1 | 2006 | 252 | 0.050 |
Why?
| | Staphylococcal Skin Infections | 1 | 2003 | 35 | 0.050 |
Why?
| | DNA | 1 | 2010 | 1459 | 0.050 |
Why?
| | Immunosuppressive Agents | 2 | 2014 | 890 | 0.050 |
Why?
| | Kidney Transplantation | 1 | 2009 | 708 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2002 | 76 | 0.050 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2006 | 257 | 0.050 |
Why?
| | Gestational Age | 1 | 2006 | 910 | 0.050 |
Why?
| | Kidney Function Tests | 1 | 2003 | 160 | 0.050 |
Why?
| | Hematopoietic Stem Cells | 1 | 2006 | 406 | 0.050 |
Why?
| | Cross-Sectional Studies | 4 | 2014 | 5472 | 0.050 |
Why?
| | Transcription Factors | 1 | 2010 | 1719 | 0.050 |
Why?
| | Clinical Protocols | 2 | 1995 | 271 | 0.050 |
Why?
| | Sulfonamides | 1 | 2005 | 513 | 0.050 |
Why?
| | Keratitis, Herpetic | 1 | 2001 | 2 | 0.050 |
Why?
| | Computer Simulation | 1 | 2006 | 978 | 0.050 |
Why?
| | Respiration, Artificial | 2 | 2014 | 645 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2002 | 1316 | 0.050 |
Why?
| | Infant, Premature | 1 | 2006 | 574 | 0.050 |
Why?
| | Osmolar Concentration | 2 | 2002 | 171 | 0.050 |
Why?
| | Kansas | 2 | 2011 | 32 | 0.040 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2001 | 21 | 0.040 |
Why?
| | Iridium Radioisotopes | 1 | 2001 | 4 | 0.040 |
Why?
| | Missouri | 2 | 2011 | 61 | 0.040 |
Why?
| | Doxycycline | 1 | 2001 | 62 | 0.040 |
Why?
| | Pharmacokinetics | 1 | 2001 | 29 | 0.040 |
Why?
| | Azithromycin | 1 | 2001 | 100 | 0.040 |
Why?
| | Arachnid Vectors | 1 | 2000 | 4 | 0.040 |
Why?
| | Hospitalization | 1 | 2010 | 2199 | 0.040 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2002 | 98 | 0.040 |
Why?
| | Aldosterone | 1 | 2000 | 45 | 0.040 |
Why?
| | Surgical Procedures, Operative | 2 | 2013 | 259 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2004 | 1477 | 0.040 |
Why?
| | Milk, Human | 1 | 2002 | 158 | 0.040 |
Why?
| | Health Plan Implementation | 1 | 2021 | 142 | 0.040 |
Why?
| | Ethionamide | 1 | 1999 | 1 | 0.040 |
Why?
| | Aminosalicylic Acid | 1 | 1999 | 1 | 0.040 |
Why?
| | Brachytherapy | 1 | 2001 | 121 | 0.040 |
Why?
| | Cycloserine | 1 | 1999 | 5 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2000 | 90 | 0.040 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2000 | 48 | 0.040 |
Why?
| | Infant, Newborn | 3 | 2007 | 6079 | 0.040 |
Why?
| | Clofazimine | 1 | 1999 | 15 | 0.040 |
Why?
| | Potassium | 1 | 2000 | 147 | 0.040 |
Why?
| | Pyrazinamide | 1 | 1999 | 12 | 0.040 |
Why?
| | Alanine Transaminase | 1 | 2000 | 157 | 0.040 |
Why?
| | Hydroxylation | 1 | 1999 | 39 | 0.040 |
Why?
| | Renal Insufficiency | 1 | 2001 | 162 | 0.040 |
Why?
| | Antibiotics, Antitubercular | 1 | 1999 | 37 | 0.040 |
Why?
| | Ethambutol | 1 | 1999 | 26 | 0.040 |
Why?
| | Drug Combinations | 1 | 2000 | 343 | 0.040 |
Why?
| | Molecular Structure | 1 | 2000 | 489 | 0.040 |
Why?
| | Mutation | 1 | 2010 | 3958 | 0.040 |
Why?
| | Isoniazid | 1 | 1999 | 63 | 0.040 |
Why?
| | Postpartum Period | 1 | 2002 | 340 | 0.040 |
Why?
| | Eye | 1 | 1999 | 108 | 0.040 |
Why?
| | Age Factors | 3 | 2013 | 3295 | 0.040 |
Why?
| | Rifampin | 1 | 1999 | 84 | 0.040 |
Why?
| | Vascular Grafting | 1 | 2018 | 13 | 0.040 |
Why?
| | Coronary Disease | 1 | 2001 | 385 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 1999 | 269 | 0.040 |
Why?
| | Venous Thrombosis | 1 | 2000 | 190 | 0.040 |
Why?
| | Drug Resistance, Viral | 1 | 1999 | 116 | 0.040 |
Why?
| | Laser Therapy | 1 | 1999 | 130 | 0.040 |
Why?
| | Length of Stay | 3 | 2014 | 1215 | 0.030 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 2012 | 86 | 0.030 |
Why?
| | Cross Reactions | 1 | 1997 | 133 | 0.030 |
Why?
| | Risk Assessment | 3 | 2016 | 3457 | 0.030 |
Why?
| | Nausea | 1 | 1998 | 111 | 0.030 |
Why?
| | Drug Compounding | 1 | 2017 | 101 | 0.030 |
Why?
| | Meningitis, Bacterial | 1 | 1997 | 47 | 0.030 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 1997 | 46 | 0.030 |
Why?
| | Stents | 1 | 2001 | 527 | 0.030 |
Why?
| | Prognosis | 2 | 2016 | 4030 | 0.030 |
Why?
| | Atovaquone | 1 | 1995 | 4 | 0.030 |
Why?
| | Public Health | 1 | 2021 | 588 | 0.030 |
Why?
| | Particle Size | 1 | 1997 | 394 | 0.030 |
Why?
| | Hip Prosthesis | 1 | 1996 | 46 | 0.030 |
Why?
| | Migraine Disorders | 1 | 1997 | 102 | 0.030 |
Why?
| | Appendicitis | 1 | 1997 | 130 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 1997 | 600 | 0.030 |
Why?
| | Internationality | 1 | 2016 | 155 | 0.030 |
Why?
| | Catheterization | 1 | 2016 | 179 | 0.030 |
Why?
| | Aminoglycosides | 1 | 1995 | 25 | 0.030 |
Why?
| | Kidney | 1 | 2003 | 1468 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1995 | 213 | 0.030 |
Why?
| | Primary Prevention | 1 | 2016 | 196 | 0.030 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2014 | 15 | 0.030 |
Why?
| | Liver Failure | 1 | 1995 | 94 | 0.030 |
Why?
| | Bradycardia | 1 | 2014 | 55 | 0.030 |
Why?
| | Standard of Care | 1 | 2014 | 72 | 0.030 |
Why?
| | Infusions, Parenteral | 1 | 2014 | 40 | 0.030 |
Why?
| | Receptors, Steroid | 1 | 2014 | 50 | 0.030 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 48 | 0.030 |
Why?
| | Age Determination by Skeleton | 1 | 1993 | 18 | 0.030 |
Why?
| | Stress Disorders, Traumatic, Acute | 1 | 2013 | 8 | 0.030 |
Why?
| | Everolimus | 1 | 2014 | 91 | 0.030 |
Why?
| | Seizures | 1 | 2017 | 426 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2014 | 88 | 0.030 |
Why?
| | Esophageal and Gastric Varices | 1 | 2013 | 40 | 0.030 |
Why?
| | Hypotension | 1 | 2014 | 122 | 0.030 |
Why?
| | Safety | 1 | 1995 | 338 | 0.030 |
Why?
| | Nutritional Status | 1 | 1996 | 350 | 0.030 |
Why?
| | Haemophilus Infections | 1 | 1993 | 42 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2014 | 389 | 0.030 |
Why?
| | Pleural Effusion | 1 | 2013 | 54 | 0.030 |
Why?
| | Demography | 1 | 2014 | 291 | 0.030 |
Why?
| | Torsades de Pointes | 1 | 2013 | 24 | 0.030 |
Why?
| | Salmonella Infections | 1 | 1993 | 57 | 0.030 |
Why?
| | Disaster Planning | 1 | 2014 | 91 | 0.030 |
Why?
| | Methylmethacrylates | 1 | 1992 | 4 | 0.020 |
Why?
| | Medical Audit | 1 | 2013 | 78 | 0.020 |
Why?
| | Rats | 1 | 2001 | 5647 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 565 | 0.020 |
Why?
| | 4-Quinolones | 1 | 1992 | 2 | 0.020 |
Why?
| | Pneumococcal Infections | 1 | 1993 | 115 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1639 | 0.020 |
Why?
| | Arthroplasty | 1 | 1992 | 52 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2074 | 0.020 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2012 | 27 | 0.020 |
Why?
| | Societies, Medical | 1 | 2016 | 820 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 1993 | 202 | 0.020 |
Why?
| | Barbiturates | 1 | 1991 | 6 | 0.020 |
Why?
| | Shock, Cardiogenic | 1 | 2012 | 63 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 1972 | 0.020 |
Why?
| | Education, Nursing, Continuing | 1 | 2011 | 53 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2016 | 766 | 0.020 |
Why?
| | Hepacivirus | 1 | 2013 | 261 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2014 | 443 | 0.020 |
Why?
| | Antibodies | 1 | 1993 | 410 | 0.020 |
Why?
| | Gastroesophageal Reflux | 1 | 2013 | 234 | 0.020 |
Why?
| | Decision Trees | 1 | 2010 | 93 | 0.020 |
Why?
| | Midwestern United States | 1 | 2010 | 45 | 0.020 |
Why?
| | Antithrombins | 1 | 2010 | 60 | 0.020 |
Why?
| | Professional Role | 1 | 2011 | 167 | 0.020 |
Why?
| | Hospitals | 1 | 1995 | 691 | 0.020 |
Why?
| | Contraindications | 1 | 2010 | 90 | 0.020 |
Why?
| | Occupational Exposure | 1 | 1993 | 341 | 0.020 |
Why?
| | Canada | 1 | 1991 | 418 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 2139 | 0.020 |
Why?
| | United Kingdom | 1 | 2010 | 318 | 0.020 |
Why?
| | Rabbits | 2 | 2001 | 794 | 0.020 |
Why?
| | Observer Variation | 1 | 2010 | 343 | 0.020 |
Why?
| | Hypoglycemia | 1 | 2013 | 445 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1916 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 2010 | 170 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1710 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2010 | 275 | 0.020 |
Why?
| | Nymph | 2 | 2001 | 6 | 0.020 |
Why?
| | Hepatitis C | 1 | 2011 | 271 | 0.020 |
Why?
| | Dopamine Antagonists | 1 | 2008 | 27 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 363 | 0.020 |
Why?
| | Sex Factors | 2 | 2009 | 2071 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 740 | 0.020 |
Why?
| | Blood Pressure | 2 | 2004 | 1786 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2010 | 786 | 0.020 |
Why?
| | Cellulitis | 1 | 2007 | 53 | 0.020 |
Why?
| | Burn Units | 1 | 2007 | 48 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 617 | 0.020 |
Why?
| | Hospitals, University | 1 | 2007 | 182 | 0.020 |
Why?
| | Patient Care Team | 1 | 2011 | 631 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 1171 | 0.020 |
Why?
| | Anxiety | 1 | 2013 | 1035 | 0.020 |
Why?
| | Colistin | 1 | 2005 | 9 | 0.020 |
Why?
| | Polymyxin B | 1 | 2005 | 20 | 0.020 |
Why?
| | Seasons | 1 | 1988 | 547 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2006 | 88 | 0.020 |
Why?
| | Antidiuretic Agents | 1 | 2005 | 6 | 0.020 |
Why?
| | Cell Count | 1 | 2006 | 324 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2014 | 5131 | 0.010 |
Why?
| | Ceftazidime | 1 | 2004 | 6 | 0.010 |
Why?
| | beta-Lactam Resistance | 1 | 2004 | 8 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2006 | 416 | 0.010 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2004 | 63 | 0.010 |
Why?
| | Methotrexate | 1 | 2006 | 260 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2031 | 0.010 |
Why?
| | Depression | 1 | 2013 | 1397 | 0.010 |
Why?
| | Tobramycin | 1 | 2004 | 52 | 0.010 |
Why?
| | Sentinel Surveillance | 1 | 2004 | 49 | 0.010 |
Why?
| | Urine | 1 | 2004 | 59 | 0.010 |
Why?
| | Hospitals, Teaching | 1 | 2004 | 118 | 0.010 |
Why?
| | Hypertension | 1 | 2013 | 1295 | 0.010 |
Why?
| | Hospitals, Urban | 1 | 2004 | 134 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1993 | 4295 | 0.010 |
Why?
| | Acute Disease | 1 | 2006 | 1007 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 4149 | 0.010 |
Why?
| | Skin Diseases | 1 | 2004 | 149 | 0.010 |
Why?
| | Hospital Mortality | 1 | 2007 | 911 | 0.010 |
Why?
| | Tablets | 1 | 2002 | 40 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3284 | 0.010 |
Why?
| | Erythema Chronicum Migrans | 1 | 2001 | 1 | 0.010 |
Why?
| | Intestinal Absorption | 1 | 2002 | 102 | 0.010 |
Why?
| | Injections, Intraperitoneal | 1 | 2001 | 114 | 0.010 |
Why?
| | Population Surveillance | 1 | 2004 | 482 | 0.010 |
Why?
| | Physicians | 1 | 2010 | 910 | 0.010 |
Why?
| | Coronary Thrombosis | 1 | 2001 | 25 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2002 | 166 | 0.010 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2001 | 141 | 0.010 |
Why?
| | Gamma Rays | 1 | 2001 | 57 | 0.010 |
Why?
| | Radiotherapy Dosage | 1 | 2001 | 268 | 0.010 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2001 | 141 | 0.010 |
Why?
| | Heart Rate | 1 | 2004 | 822 | 0.010 |
Why?
| | Trigeminal Ganglion | 1 | 1999 | 25 | 0.010 |
Why?
| | Inhibitory Concentration 50 | 1 | 1999 | 90 | 0.010 |
Why?
| | Secondary Prevention | 1 | 2001 | 233 | 0.010 |
Why?
| | Virus Latency | 1 | 1999 | 80 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2003 | 746 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2013 | 2531 | 0.010 |
Why?
| | Homeostasis | 1 | 2002 | 621 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2001 | 1236 | 0.010 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2001 | 463 | 0.010 |
Why?
| | Serum Albumin | 1 | 1996 | 150 | 0.010 |
Why?
| | Elective Surgical Procedures | 1 | 1996 | 179 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2001 | 1046 | 0.010 |
Why?
| | Wrist | 1 | 1993 | 54 | 0.010 |
Why?
| | Hand | 1 | 1993 | 156 | 0.010 |
Why?
| | Saliva | 1 | 1993 | 242 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1996 | 2654 | 0.000 |
Why?
|
|
Fish's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|